High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy - Wikidata - awgldk - TriplyDB

High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy

High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy

http://www.wikidata.org/entity/Q58321557

about

Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention Structural Context of Disease-Associated Mutations and Putative Mechanism of Autoinhibition Revealed by X-Ray Crystallographic Analysis of the EZH2-SET Domain Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis Increased HIF-1alpha expression in tumor cells and lymphocytes of tumor microenvironments predicts unfavorable survival in esophageal squamous cell carcinoma patients Role of EZH2 polymorphisms in esophageal squamous cell carcinoma risk in Han Chinese population.Association of decreased expression of long non-coding RNA LOC285194 with chemoradiotherapy resistance and poor prognosis in esophageal squamous cell carcinoma.The prognostic role of EZH2 expression in rectal cancer patients treated with neoadjuvant chemoradiotherapy The telomere/telomerase binding factor PinX1 is a new target to improve the radiotherapy effect of oesophageal squamous cell carcinomas.The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma Enhancer of zeste homolog 2 as an independent prognostic marker for cancer: a meta-analysis Prognostic significance of histone methyltransferase enhancer of zeste homolog 2 in patients with cervical squamous cell carcinoma.Enhancer of zeste homolog 2 silencing inhibits tumor growth and lung metastasis in osteosarcoma.Higher heat shock factor 1 expression in tumor stroma predicts poor prognosis in esophageal squamous cell carcinoma patients Increased WNT6 expression in tumor cells predicts unfavorable survival in esophageal squamous cell carcinoma patients MicroRNA-98 and microRNA-214 post-transcriptionally regulate enhancer of zeste homolog 2 and inhibit migration and invasion in human esophageal squamous cell carcinoma Role of E2F-1 and its involving pathway in esophageal squamous cell carcinoma.The relationship between EZH2 expression and microRNA-31 in colorectal cancer and the role in evolution of the serrated pathway High expression of long non-coding RNA AFAP1-AS1 predicts chemoradioresistance and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy The JAZF1-SUZ12 fusion protein disrupts PRC2 complexes and impairs chromatin repression during human endometrial stromal tumorogenesis Epigenetic and genetic alterations-based molecular classification of head and neck cancer.Molecular genetics of myelofibrosis and its associated disease phenotypes.Epigenetic silencing and activation of transcription: influence on the radiation sensitivity of glioma cell lines.HOTAIR, a prognostic factor in esophageal squamous cell carcinoma, inhibits WIF-1 expression and activates Wnt pathway.Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma.EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin.Overexpression of maelstrom promotes bladder urothelial carcinoma cell aggressiveness by epigenetically downregulating MTSS1 through DNMT3B.IncRNA H19 promotes tongue squamous cell carcinoma progression through β-catenin/GSK3β/EMT signaling via association with EZH2.Neutrophil-to-lymphocyte ratio as a prognostic biomarker for patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer.Elevated HBXIP expression is associated with aggressive phenotype and poor prognosis in esophageal squamous cell carcinoma.Correlations of EZH2 and SMDY3 Gene Polymorphisms with Breast Cancer Susceptibility and Prognosis.Down-regulation of long non-coding RNA ESCCAL_1 inhibits tumor growth of esophageal squamous cell carcinoma in a xenograft mouse model.The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer.EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.

P2860

Q26994739-4A04BA74-B6E9-48F4-A149-72EC4D1EB366 Q27681087-87A597B5-5ADD-4117-B799-95659D6F7702 Q27853296-B19C80DC-2744-40DF-A08F-83C84428DAAF Q34029008-97971172-F535-4929-B5CF-FE859B8CA183 Q34072487-2F5ED430-3B53-4122-9D01-29D1F9E4A9FC Q34135956-BE2A9B5E-9B58-492B-8977-4396D0021785 Q34175876-1A507111-9044-4523-B9F1-EA2457E54CAE Q34323827-7E8D428E-79F2-44EE-B9EE-4764D67CDB48 Q35159486-4A335566-77E2-4909-B012-343A8603533F Q35606640-C3D9E5CA-04B0-45F2-8432-C46F3644503B Q35870148-4AF1DFA4-B3DC-4261-A703-81B642F7263D Q35942323-47EC2E93-07DF-40F8-B543-61DD9E90E90C Q36223509-E66CC71C-6A70-4BD8-B6F2-579F982284D2 Q36261828-CC0177DA-C203-4641-A87A-BBC6D914F33A Q36394758-6CA24028-A135-43F3-8FDD-9B459CAF3911 Q36439397-63253648-C89A-4824-B317-5DFCAA4E2F4D Q37022273-7EA746C4-528B-4AD4-AA20-F890D6E3B6B2 Q37418043-A711F5E9-969A-4337-A8C8-067F911B38DE Q37706132-0659C4F2-2FE6-4E0E-A899-62E33BCD78FD Q37999072-EBD05893-55E3-475F-9B3E-5B547106970B Q38208010-66F6F135-EA3B-46A6-AD92-1A00B840C707 Q38723183-D8525AF9-2630-4652-8E9A-FF3AD1BB76FA Q39080607-C2E4C44D-ADA4-4E7F-9577-F19E1F6908C7 Q39459774-5B1357F4-0996-4E31-BB5C-0AE1F494E259 Q39521859-0E6FF8BF-88FF-4B50-8309-83028BF0AD3A Q39764810-23625859-5088-4424-BBD9-F655ACF3CF7C Q41126655-B7E8B31D-A4FB-45F8-863D-C0920A6E9408 Q41777743-34757144-0867-4E67-8DC1-19236724E241 Q41942526-8D4C32AB-37AE-4B71-9FD6-39644638B60C Q47098463-12D447D8-A196-4ABA-ACC7-789F8A1E21E4 Q47726980-D55CCB23-854F-4B64-BFDE-441AB3C13061 Q49355253-ED933E05-57A3-43A7-B269-4D033E9216BD Q53223003-7042DBD7-E445-4BFE-9651-53E98AFFE05B Q54417851-4813E9B7-DD0D-4B83-AEA4-35DA65066617

P2860

High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy

http://www.wikidata.org/entity/Q58321557

description

im November 2009 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 01 July 2010

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в листопаді 2009

@uk

name

High expression of EZH2 is ass ...... h definitive chemoradiotherapy

@en

High expression of EZH2 is ass ...... h definitive chemoradiotherapy

@nl

type

label

High expression of EZH2 is ass ...... h definitive chemoradiotherapy

@en

High expression of EZH2 is ass ...... h definitive chemoradiotherapy

@nl

prefLabel

High expression of EZH2 is ass ...... h definitive chemoradiotherapy

@en

High expression of EZH2 is ass ...... h definitive chemoradiotherapy

@nl

P1433

Q58321557-E29BE1E5-8BDC-40FA-A2DE-153F491A8E8A

P1476

Q58321557-597E1DF4-F292-4C47-8DCE-AB9C4FAD2754

P2093

Q58321557-1247B568-5F6D-4F93-9FED-07CF2C3CFC4E

Q58321557-126E1D5F-E161-4C86-B20B-BD433725F48A

Q58321557-1E42BF9C-0B86-4C05-8F3C-CA0E88301816

Q58321557-48365F8E-C8BB-4BE2-8852-6172F6CA9235

Q58321557-5391617E-4315-4359-BD04-3CB91188C1AD

Q58321557-80F6C745-21D9-447B-B626-81B256FCF751

Q58321557-C0EFE5CC-26CD-4F59-AF88-EBEE0773BC84

Q58321557-C0F99396-F9EF-48F0-906B-7F696BA5A42A

Q58321557-CCEBD6FA-2829-4CE6-9FE0-C7F9D0885382

Q58321557-D3FA76FE-0DE4-4E93-A010-065FC2D6F3FD

P2860

Q58321557-0C67F0B2-E1D0-4E5F-B945-D7ABCA041E0A

Q58321557-15F3BF83-60D7-42CC-8951-B6747BE53C50

Q58321557-16D99E5C-5DD3-4853-B303-047E9887ABDC

Q58321557-1B96EB9B-F8B4-412E-822C-D98EE7DF9769

Q58321557-1F76E72C-221A-4A0D-9E1A-C1D531B118B2

Q58321557-278540C2-01D9-44DD-A155-2504E752F739

Q58321557-3556E576-4980-4D76-A0C1-01A8C533A155

Q58321557-3BD5233A-BCF0-4E00-AFD7-A66CCFE7F349

Q58321557-47FAE94D-9BE9-4222-8303-EC966B49AC64

Q58321557-55FDA762-9617-445A-922D-D0E08B595A3F

P304

Q58321557-6ABF4277-D65C-4E00-8E05-F26AEC9F0D99

P31

Q58321557-CC233EE7-6946-4954-B3F8-7488DE0F0D66

P356

Q58321557-CDC4F9C2-5DBF-4EC9-908C-839AA3DDF5FA

P433

Q58321557-16A09DBB-DB09-4B93-ADE7-9C2E7F2C570A

P478

Q58321557-B5A2488D-D79B-4F0A-A694-ABEE5C816625

P50

Q58321557-956F737C-103F-4A4E-A554-77BA0CE2DE67

Q58321557-D54F43AD-C32A-4DD3-9643-AFE713377E33

Q58321557-F5A2D134-FCD6-4D66-B43A-F988FA643EA3

P577

Q58321557-1C281C2C-FE01-48C1-B3F6-F3912F114748

P698

Q58321557-50603769-386B-41DD-9178-A218E4613200

P921

Q58321557-47308971-B0AE-4D51-9847-0645A8B4E962

P356

P1433

International Journal of Cancer

P1476

High expression of EZH2 is ass ...... h definitive chemoradiotherapy

@en

P2093

Bin-Kui Li

http://www.w3.org/2001/XMLSchema#string

Dan Xie

http://www.w3.org/2001/XMLSchema#string

Hsiang-Fu Kung

http://www.w3.org/2001/XMLSchema#string

Lan-Jun Zhang

http://www.w3.org/2001/XMLSchema#string

Li-Ru He

http://www.w3.org/2001/XMLSchema#string

Meng-Zhong Liu

http://www.w3.org/2001/XMLSchema#string

Wei-Hua Jia

http://www.w3.org/2001/XMLSchema#string

Yi-Ji Liao

http://www.w3.org/2001/XMLSchema#string

Yi-Xin Zeng

http://www.w3.org/2001/XMLSchema#string

Ying Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics, 2002

Control of developmental regulators by Polycomb in human embryonic stem cells

Gamma-linolenic acid alters Ku80, E2F1, and bax expression and induces micronucleus formation in C6 glioma cells in vitro

The polycomb group protein EZH2 is involved in progression of prostate cancer

The human EZH2 gene: genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders.

EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer

Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer.

Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.

Increased E2F-1 expression via tumour cell proliferation and decreased apoptosis are correlated with adverse prognosis in patients with squamous cell carcinoma of the oesophagus.

Treatment of localized esophageal cancer.

P304

138-147

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.25031

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

127

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19904743

http://www.w3.org/2001/XMLSchema#string

P921